The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

South Korea: A large population-based study from South Korea has revealed a significant association between cholecystectomy ...

Often symptomless, fatty liver disease is becoming a leading cause of liver cancer. Learn the role of daily habits, early ...

A new analysis from the Chile BiLS study evaluated the reliability of ultrasound imaging for diagnosing SLD in a high-risk ...

Fatty liver disease, medically called metabolic dysfunction-associated steatotic liver disease (MASLD), affects millions globally. Around one in four adults worldwide has this hidden condition ...

New research highlights a significant link between metabolic dysfunction-associated steatotic liver disease (MASLD), formerly ...

China: A large-scale U.S. analysis has revealed that people living with both type 2 diabetes (T2DM) and chronic kidney ...

Medically reviewed by Robert Burakoff, MD Fatty liver disease is a health condition in which fat builds up in the liver. This ...

Steatotic liver disease (SLD) was highly prevalent among adults with cardiometabolic risk factors, prolonged alcohol intake, or both combined and affected 70% of participants overall.

Source Reference: Ochoa-Allemant P, et al "Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease" JAMA Intern Med 2025; DOI: 10.1001/jamainternmed.2025.1809.